TEREX CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TEREX CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.42B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.13B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.15B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.42B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $3.89B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $3.08B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $4.35B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $4.52B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $3.79B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $4.44B | Feb 25, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.42B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.13B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.15B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.42B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $3.89B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $3.08B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $4.35B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $4.52B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $3.79B | Feb 14, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $4.42B | Feb 18, 2011 |
| FY2009 | Dec 31, 2009 | $4.04B | Feb 24, 2010 |
| FY2009 | Dec 31, 2008 | $8.39B | Feb 24, 2010 |
| FY2009 | Dec 31, 2007 | $7.98B | Feb 24, 2010 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.07B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $871.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $757.40M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $539.30M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $887.80M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $961.90M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $767.30M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $712.40M | Feb 25, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $335.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $518.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $300.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $220.90M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | ($10.60M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $54.40M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $113.70M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $128.70M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | ($176.10M) | Feb 25, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $475.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $526.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $637.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $420.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $328.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $68.40M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $335.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $412.50M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $228.20M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | ($141.80M) | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $25.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $28.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $22.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $52.20M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $58.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $72.40M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $63.20M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $55.60M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $86.20M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $576.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $542.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $540.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $451.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $429.40M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $470.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $552.80M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $549.40M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $539.10M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $678.20M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $440.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $326.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $459.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $261.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $293.40M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $225.40M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $173.40M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $94.20M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $153.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $377.10M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.14B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.73B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $3.62B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $3.12B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $2.86B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.03B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.20B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $3.49B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.46B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $5.01B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.04B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.90B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.94B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.94B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $1.75B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $2.11B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $2.26B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $2.62B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.24B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $3.49B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $932.30M | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $860.50M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.22B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.48B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.88B | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | $2.01B | Feb 22, 2016 |
| FY2013 | Dec 31, 2013 | $2.19B | Feb 23, 2015 |
| FY2013 | Dec 31, 2012 | $2.01B | Feb 25, 2014 |
| FY2012 | Dec 31, 2011 | $1.91B | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $2.08B | Feb 29, 2012 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $295.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $284.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $280.10M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $275.40M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $269.90M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $265.20M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $273.60M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $259.70M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.14B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.96B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.68B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $936.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $750.30M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $771.40M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $749.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.00B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.90B | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $772.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $388.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $371.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $304.10M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $266.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $665.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $535.10M | Feb 12, 2021 |
| FY2020 | Dec 31, 2018 | $339.50M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $571.60M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $428.50M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.59B | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $2.60B | Feb 7, 2025 |
| FY2023 | Dec 31, 2023 | $600.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2022 | $777.30M | Feb 10, 2023 |
| FY2021 | Dec 31, 2021 | $670.60M | Feb 11, 2022 |
| FY2020 | Dec 31, 2020 | $1.17B | Feb 12, 2021 |
| FY2019 | Dec 31, 2019 | $1.17B | Feb 14, 2020 |
| FY2018 | Dec 31, 2018 | $1.22B | Feb 25, 2019 |
| FY2017 | Dec 31, 2017 | $981.70M | Feb 16, 2018 |
| FY2016 | Dec 31, 2016 | $1.57B | Feb 27, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Feb 25, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Feb 25, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $46.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $43.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $36.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $33.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $8.40M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $31.40M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $30.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $29.50M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $30.00M | Feb 25, 2019 |